These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33161040)

  • 1. In-vitro and particle image velocimetry studies of dry powder inhalers.
    Dos Reis LG; Chaugule V; Fletcher DF; Young PM; Traini D; Soria J
    Int J Pharm; 2021 Jan; 592():119966. PubMed ID: 33161040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A counter-swirl design concept for dry powder inhalers.
    Chaugule V; Dos Reis LG; Fletcher DF; Young PM; Traini D; Soria J
    Int J Pharm; 2024 Jan; 650():123694. PubMed ID: 38081562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancement of a Positive-Pressure Dry Powder Inhaler for Children: Use of a Vertical Aerosolization Chamber and Three-Dimensional Rod Array Interface.
    Farkas D; Bonasera S; Bass K; Hindle M; Longest PW
    Pharm Res; 2020 Aug; 37(9):177. PubMed ID: 32862295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial Development of an Air-Jet Dry Powder Inhaler for Rapid Delivery of Pharmaceutical Aerosols to Infants.
    Howe C; Hindle M; Bonasera S; Rani V; Longest PW
    J Aerosol Med Pulm Drug Deliv; 2021 Feb; 34(1):57-70. PubMed ID: 32758026
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of Dry Powder Inhaler Patient Interfaces for Improved Aerosol Delivery to Children.
    Bass K; Longest W
    AAPS PharmSciTech; 2020 May; 21(5):157. PubMed ID: 32451773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational investigation of particle penetration and deposition pattern in a realistic respiratory tract model from different types of dry powder inhalers.
    Kim YH; Li DD; Park S; Yi DS; Yeoh GH; Abbas A
    Int J Pharm; 2022 Jan; 612():121293. PubMed ID: 34808267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From laminar to turbulent flow in a dry powder inhaler: The effect of simple design modifications.
    Singh G; Tang P; Cheng S; Chan HK; Kourmatzis A
    Int J Pharm; 2022 Mar; 616():121556. PubMed ID: 35131350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a High-Dose Infant Air-Jet Dry Powder Inhaler (DPI) with Passive Cyclic Loading of the Formulation.
    Howe C; Momin MAM; Aladwani G; Hindle M; Longest PW
    Pharm Res; 2022 Dec; 39(12):3317-3330. PubMed ID: 36253630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the mouthpiece and chamber of Turbuhaler® on the aerosolization of API-only powder formulations.
    Zhu Q; Gou D; Chan HK; Kourmatzis A; Yang R
    Int J Pharm; 2023 Apr; 637():122871. PubMed ID: 36948474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the Use of Computational Fluid Dynamics (CFD) Modelling to Design Improved Dry Powder Inhalers.
    Fletcher DF; Chaugule V; Gomes Dos Reis L; Young PM; Traini D; Soria J
    Pharm Res; 2021 Feb; 38(2):277-288. PubMed ID: 33575958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of powder residence time for the aerosol delivery performance of a commercial dry powder inhaler Aerolizer(®).
    Jiang L; Tang Y; Zhang H; Lu X; Chen X; Zhu J
    J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):265-79. PubMed ID: 22280548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols.
    Yaqoubi S; Chan HK; Nokhodchi A; Dastmalchi S; Alizadeh AA; Barzegar-Jalali M; Adibkia K; Hamishehkar H
    Int J Pharm; 2021 Jun; 602():120568. PubMed ID: 33812969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
    Kolanjiyil AV; Kleinstreuer C; Sadikot RT
    Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining experimental and computational techniques to understand and improve dry powder inhalers.
    Chaugule V; Wong CY; Inthavong K; Fletcher DF; Young PM; Soria J; Traini D
    Expert Opin Drug Deliv; 2022 Jan; 19(1):59-73. PubMed ID: 34989629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Air-Jet Dry Powder Insufflator for High-Efficiency Aerosol Delivery to Rats.
    Pangeni R; Hassan AAM; Farkas D; Sudarjat H; Longest W; Hindle M; Xu Q
    Mol Pharm; 2023 Apr; 20(4):2207-2216. PubMed ID: 36938947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an Inline Dry Powder Inhaler for Oral or Trans-Nasal Aerosol Administration to Children.
    Farkas D; Hindle M; Bonasera S; Bass K; Longest W
    J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):83-98. PubMed ID: 31464559
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing Aerosolization Using Computational Fluid Dynamics in a Pediatric Air-Jet Dry Powder Inhaler.
    Bass K; Farkas D; Longest W
    AAPS PharmSciTech; 2019 Nov; 20(8):329. PubMed ID: 31676991
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Howe C; Momin MAM; Bass K; Aladwani G; Bonasera S; Hindle M; Longest PW
    J Aerosol Med Pulm Drug Deliv; 2022 Aug; 35(4):196-211. PubMed ID: 35166601
    [No Abstract]   [Full Text] [Related]  

  • 20. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
    Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
    Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.